Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms

A Inserra, D De Gregorio, G Gobbi, M Nader - Pharmacological Reviews, 2021 - Elsevier
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

VDAC, a multi-functional mitochondrial protein regulating cell life and death

V Shoshan-Barmatz, V De Pinto, M Zweckstetter… - Molecular aspects of …, 2010 - Elsevier
Research over the past decade has extended the prevailing view of the mitochondrion to
include functions well beyond the generation of cellular energy. It is now recognized that …

Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms

R Moratalla, A Khairnar, N Simola, N Granado… - Progress in …, 2017 - Elsevier
Amphetamine-related drugs, such as 3, 4-methylenedioxymethamphetamine (MDMA) and
methamphetamine (METH), are popular recreational psychostimulants. Several preclinical …

The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA,“ecstasy”)

AR Green, AO Mechan, JM Elliott, E O'Shea… - Pharmacological …, 2003 - Elsevier
Abstract The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA,
ecstasy) is a popular recreational drug among young people, particularly those involved in …

Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview

JP Capela, H Carmo, F Remião, ML Bastos… - Molecular …, 2009 - Springer
Abstract “Ecstasy”[(±)-3, 4-methylenedioxymethamphetamine, MDMA, XTC, X, E] is a
psychoactive recreational hallucinogenic substance and a major worldwide drug of abuse …

The serotonergic system in Parkinson's disease

P Huot, SH Fox, JM Brotchie - Progress in neurobiology, 2011 - Elsevier
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …

Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms

J Lyles, JL Cadet - Brain Research Reviews, 2003 - Elsevier
Methylenedioxymethamphetamine (MDMA, Ecstasy) is a very popular drug of abuse. This
has led to new intense concerns relevant to its nefarious neuropsychiatric effects. These …

The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and d-amphetamine

T Steinkellner, M Freissmuth, HH Sitte, T Montgomery - 2011 - degruyter.com
Abstract Amphetamine ('Speed'), methamphetamine ('Ice') and its congener 3, 4-
methylenedioxymethamphetamine (MDMA;'Ecstasy') are illicit drugs abused worldwide for …

Kinetics, mechanism, and inhibition of monoamine oxidase

RR Ramsay, A Albreht - Journal of Neural Transmission, 2018 - Springer
Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide
variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs …

Dark classics in chemical neuroscience: 3, 4-methylenedioxymethamphetamine

LE Dunlap, AM Andrews, DE Olson - ACS chemical neuroscience, 2018 - ACS Publications
Better known as “ecstasy”, 3, 4-methylenedioxymethamphetamine (MDMA) is a small
molecule that has played a prominent role in defining the ethos of today's teenagers and …